Associated tags: Patient, Health, Medical Devices, Health Technology, Disclosure, Regulation Fair Disclosure, Regulation, Conference, Managed Care, News, Biotechnology
Locations: UNITED STATES, NORTH AMERICA, CALIFORNIA
General Health,
Health Technology,
Health,
Medical Devices,
Pocs,
ICER,
POC,
Survival,
Quality of life,
Patient,
Medical imaging With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to date.
Key Points:
- With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to date.
- Additionally, based on the incremental cost-effectiveness ratio (ICER), POCs were cost-effective compared to stationary concentrators, compressed tanks, and liquid oxygen.
- “The study highlights what we have known anecdotally about portable oxygen therapies, and Inogen devices,” said Kevin Smith, President and Chief Executive Officer.
- “We have long believed that mobile oxygen therapies, primarily portable oxygen concentrators, are associated with improved health outcomes, affordability, and patient quality of life.
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024.
Key Points:
- Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024.
- GAAP net loss for the first quarter of 2024 was $14.6 million compared to GAAP net loss of $20.3 million in the first quarter of 2023.
- Adjusted EBITDA was a negative $7.6 million in the first quarter of 2024 compared to a negative $11.8 million in the first quarter of 2023.
- An explanation of these non-GAAP financial measures is also included below under the heading “Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures.”
For the second quarter of 2024, Inogen expects revenue to be in the range of $81 million to $84 million.
Retrieved on:
Wednesday, April 10, 2024
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2024 financial results after the market closes on Tuesday, May 7, 2024.
Key Points:
- Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2024 financial results after the market closes on Tuesday, May 7, 2024.
- On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m.
- Individuals interested in listening to the conference call may do so by dialing:
Please reference Inogen to join the call.
- A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through May 14, 2024.
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 23rd Annual Needham Virtual Healthcare Conference.
Key Points:
- Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 23rd Annual Needham Virtual Healthcare Conference.
- Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 9, 2024, at 9:30 a.m. Eastern Time.
- A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website.
- Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/ , as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
Key Points:
- The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
- Subject to Mr. Bourque’s continued service with Inogen, one-third of the RSUs will vest annually over three years.
- Subject to Mr. Bourque’s continued service with Inogen, the PSUs will vest based on Inogen’s achievement of specified performance goals.
- The awards were granted pursuant to stand-alone inducement award agreements outside of the company’s 2023 Equity Incentive Plan but are generally subject to the same terms and conditions that apply to awards granted under the company’s 2023 Equity Incentive Plan.
Retrieved on:
Tuesday, February 27, 2024
Managed Care,
Health Technology,
Health,
Medical Devices,
Growth,
Regulation,
GAAP,
Disclosure,
Regulation Fair Disclosure,
Conference,
Video game GAAP net loss for the fourth quarter of 2023 was $26.6 million compared to GAAP net loss of $56.6 million in the fourth quarter of 2022.
Key Points:
- GAAP net loss for the fourth quarter of 2023 was $26.6 million compared to GAAP net loss of $56.6 million in the fourth quarter of 2022.
- Adjusted net loss for the fourth quarter of 2023 was $19.4 million compared to adjusted net loss of $13.0 million in the fourth quarter of 2022.
- Adjusted EBITDA was a negative $17.3 million in the fourth quarter of 2023 compared to a negative $10.6 million in the fourth quarter of 2022.
- Inogen will issue fourth quarter and full-year 2023 financial results after the market closes on Tuesday, February 27, 2024.
Retrieved on:
Tuesday, January 30, 2024
Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Tuesday, February 27, 2024.
Key Points:
- Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Tuesday, February 27, 2024.
- On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m.
- Individuals interested in listening to the conference call may do so by dialing:
Please reference Inogen to join the call.
- To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/ .
Retrieved on:
Wednesday, January 24, 2024
Health Technology,
Health,
Medical Supplies,
Senior,
Patient,
Bentley University,
CFO,
Analogic Corporation,
Treasurer,
Chase,
KKR,
CCF,
Interim,
Chase Corporation,
Axcelis Technologies,
Management Mr. Bourque has served as Treasurer and Chief Financial Officer of Chase Corporation (formally NYSE:CCF) now owned by KKR & Co. Inc.
Key Points:
- Mr. Bourque has served as Treasurer and Chief Financial Officer of Chase Corporation (formally NYSE:CCF) now owned by KKR & Co. Inc.
- Mr. Bourque has served as Chief Financial Officer and Treasurer of Chase Corporation since 2021.
- He also served as Chief Financial Officer of Keystone Dental, Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation from 2014 to 2018 and as Vice President of Finance for Axcelis Technologies from 2011 to 2014.
- Kevin Smith, President and Chief Executive Officer of Inogen said, “I am incredibly excited to announce Michael as the new Chief Financial Officer of Inogen.
Retrieved on:
Monday, November 13, 2023
Biotechnology,
Medical Devices,
Health,
Health Technology,
Managed Care,
Organization,
History,
Patient,
Piper Sandler Companies,
Conference,
Growth,
Management,
Teleflex Mr. Smith brings more than 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses, and a history of success in executing value-creating transformations across organizations.
Key Points:
- Mr. Smith brings more than 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses, and a history of success in executing value-creating transformations across organizations.
- Mr. Smith previously held senior positions at Sensium Healthcare Ltd., Teleflex, Hillrom Holdings and ZOLL Medical Corporation.
- “Inogen is a global leader in portable oxygen therapy solutions, with a large and growing market, and leading patient-centric product portfolio,” said Elizabeth Mora, Chairperson of the Board.
- I believe Inogen has a solid foundation, with leading products, and significant potential to make innovative respiratory solutions the standard of care to improve patient health.
Retrieved on:
Thursday, November 9, 2023
Managed Care,
Health Technology,
Health,
Medical Devices,
Disclosure,
Baozou Big News Events,
Regulation,
Conference,
News,
Regulation Fair Disclosure,
Pharmaceutical industry Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following investor conferences:
Key Points:
- Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following investor conferences:
Stifel 2023 Healthcare Conference on Wednesday, November 15 at 10:20 a.m. Eastern Time
Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29 at 10:30 a.m. Eastern Time
A live webcast and archived recording of each presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website.
- Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/ , as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
- For more information, visit http://investor.inogen.com/ .
